c-Myc在肿瘤中的表达及功能

doi:10.3760/cma.j.issn.1673-422X.2017.04.009

摘要/Abstract

摘要： 原癌蛋白c-Myc在多种组织和细胞中均有表达，其功能的异常与淋巴瘤、前列腺癌、乳腺癌、胰腺癌等多种肿瘤的发生和预后密切相关。随着对c-Myc在肿瘤中的表达及功能研究的不断深入，通过靶向c-Myc治疗肿瘤取得了较大进展。

Abstract: The proto oncogene c-Myc is expressed in many kinds of organs, and its dysfunction is closely related to the occurrence and prognosis of lymphoma, prostatic cancer, breast cancer and pancreatic cancer. With a large number of studies focus on the expression and function of c-Myc in tumor, the treatment of tumor by targeting c-Myc has made a wealth of progress.

Key words: Neoplasms, Proto-oncogene proteins c-myc, Targeted treatment

俞今晶,来纯云. c-Myc在肿瘤中的表达及功能[J]. 国际肿瘤学杂志, 2017, 44(4): 278-280.

Yu Jinjing, Lai Chunyun. Expression and function of c-Myc in tumor[J]. Journal of International Oncology, 2017, 44(4): 278-280.

参考文献

［1］ Hsieh AL, Walton ZE, Altman BJ, et al. MYC and metabolism on the path to cancer［J］. Semin Cell Dev Biol, 2015, 43: 11-21. DOI: 10.1038/nrc2231. ［2］ Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc［J］. Cell, 2012, 151(1): 56-67. DOI: 10.1016/j.cell.2012.08.026. ［3］ Dang CV. MYC on the path to cancer［J］. Cell, 2012, 149(1): 22-35. DOI: 10.1016/j.cell.2012.03.003. ［4］ Ott G. Impact of MYC on malignant behavior［J］. Hematology Am Soc Hematol Educ Program, 2014, 2014(1): 100-106. DOI: 10.1182/asheducation-2014.1.100. ［5］ Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis［J］. J Intern Med, 2014, 276(1): 52-60. DOI: 10.1111/joim.12237. ［6］ Xu X, Zhang L, Wang Y, et al. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review［J］. Int J Clin Exp Pathol, 2013, 6(4): 788-794. ［7］ Dunleavy K. Aggressive B cell lymphoma: optimal therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL［J］. Curr Treat Options Oncol, 2015, 16(12): 58. DOI: 10.1007/s11864-015-0374-0. ［8］ Landsburg DJ, Falkiewicz MK, Petrich AM, et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable［J］. Br J Haematol, 2016, 175(4): 631-640. DOI: 10.1111/bjh.14282. ［9］ Suk FM, Lin SY, Lin RJ, et al. Bortezomib inhibits Burkitt′s lym-phoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression［J］. Oncotarget, 2015, 6(28): 25988-26001. DOI: 10.18632/oncotarget.4620. ［10］ Hubbard GK, Mutton LN, Khalili M, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer［J］. Cancer Res, 2016, 76(2): 283-292. DOI: 10.1158/0008-5472.CAN-14-3280. ［11］ Ellis L, Ku S, Li Q, et al. Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer［J］. Prostate, 2016, 76(13): 1192-1202. DOI: 10.1002/pros.23206. ［12］ Zeng W, Sun H, Meng F, et al. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer［J］. Int J Clin Exp Pathol, 2015, 8(2): 1878-1888. ［13］ Akinyeke T, Matsumura S, Wang X, et al. Metformin targets c-MYC oncogene to prevent prostate cancer［J］. Carcinogenesis, 2013, 34(12): 2823-2832. DOI: 10.1093/carcin/bgt307. ［14］ Xu LP, Sun Y, Li W, et al. MYC and MXI1 protein expression: potential prognostic significance in women with breast cancer in China［J］. Oncol Res Treat, 2014, 37(3): 118-123. DOI: 10.1159/000360207. ［15］ Shen L, O′Shea JM, Kaadige MR, et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP［J］. Proc Natl Acad Sci USA, 2015, 112(17): 5425-5430. DOI: 10.1073/pnas.1501555112. ［16］ Nair R, Roden DL, Teo WS, et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer［J］. Oncogene, 2014, 33(30): 3992-4002. DOI: 10.1038/onc.2013.368. ［17］ He TL, Zhang YJ, Jiang H, et al. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer［J］. Med Oncol, 2015, 32(7): 187. DOI: 10.1007/s12032-015-0633-8. ［18］ Stellas D, Szabolcs M, Koul S, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer［J］. J Natl Cancer Inst, 2014, 106(12): dju320. DOI: 10.1093/jnci/dju320. ［19］ He C, Jiang H, Geng S, et al. Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer［J］. Int J Clin Exp Pathol, 2014, 7(2): 742-750. ［20］ Wang H, Cao F, Li X, et al. miR-320b suppresses cell proliferation by targeting c-Myc in human colorectal cancer cells［J］. BMC Cancer, 2015, 15: 748. DOI: 10.1186/s12885-015-1728-5. ［21］ Castell A, Larsson LG. Targeting MYC translation in colorectal cancer［J］. Cancer Discov, 2015, 5(7): 701-703. DOI: 10.1158/2159-8290.CD-15-0660. ［22］ Wang J, Ma X, Jones HM, et al. Evaluation of the antitumor effects of c-MycMax heterodimerization inhibitor 100258F4 in ovarian cancer cells［J］. J Transl Med, 2014, 12: 226. DOI: 10.1186/s12967-014-0226-x. ［23］ Reyes-Gonzalez JM, Armaiz-Pe-a GN, Mangala LS, et al. Targeting c-MYC in platinum-resistant ovarian cancer［J］. Mol Cancer Ther, 2015, 14(10): 2260-2269. DOI: 10.1158/1535-7163.MCT-14-0801. ［24］ Hall Z, Ament Z, Wilson CH, et al. Myc expression drives aberrant lipid metabolism in lung cancer［J］. Cancer Res, 2016, 76(16): 4608-4618. DOI: 10.1158/00085472.CAN-15-3403. ［25］ Dauch D, Rudalska R, Cossa G, et al. A Myc-aurora kinase a protein complex represents an actionable drug target in p53-altered liver cancer［J］. Nat Med, 2016, 22(7): 744-753. DOI: 10.1038/nm.4107. ［26］ Xia B, Tian C, Guo S, et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia［J］. Leuk Res, 2015, 39(1): 92-99. DOI: 10.1016/j.leukres.2014.11.004. ［27］ Hart JR, Garner AL, Yu J, et al. Inhibitor of MYC identified in a Kr-hnke pyridine library［J］. Proc Natl Acad Sci USA, 2014, 111(34): 12556-12561. DOI: 10.1073/pnas.1319488111. ［28］ Baker EK, Taylor S, Gupte A, et al. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells［J］. Sci Rep, 2015, 5: 10120. DOI: 10.1038/srep10120. ［29］ Arshad Z, Smith J, Roberts M, et al. Open access could transform drug discovery: a case study of JQ1［J］. Expert Opin Drug Discov, 2016, 11(3): 321-332. DOI: 10.1517/17460441.2016.1144587. ［30］ Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor［J］. Nature, 2014, 511(7511): 616-620. DOI: 10.1038/nature13393.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.